FDA allows use of Genentech's Rituxan for 2 orphan diseases

04/19/2011 | Reuters

The FDA authorized Genentech to promote blockbuster drug Rituxan as a treatment for Wegener's granulomatosis and microscopic polyangiitis, which are rare vasculitis-causing disorders. Rituxan is already used in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ